Strs Ohio decreased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 12.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 219,570 shares of the specialty pharmaceutical company’s stock after selling 30,000 shares during the period. Strs Ohio owned approximately 0.44% of Supernus Pharmaceuticals worth $5,429,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Louisiana State Employees Retirement System increased its stake in shares of Supernus Pharmaceuticals by 43.1% in the third quarter. Louisiana State Employees Retirement System now owns 21,900 shares of the specialty pharmaceutical company’s stock worth $542,000 after buying an additional 6,600 shares in the last quarter. Capital Management Corp VA increased its stake in shares of Supernus Pharmaceuticals by 79.0% in the third quarter. Capital Management Corp VA now owns 63,795 shares of the specialty pharmaceutical company’s stock worth $1,578,000 after buying an additional 28,165 shares in the last quarter. Insight Capital Research & Management Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the third quarter worth $3,499,000. Rice Hall James & Associates LLC increased its stake in shares of Supernus Pharmaceuticals by 11.2% in the third quarter. Rice Hall James & Associates LLC now owns 604,242 shares of the specialty pharmaceutical company’s stock worth $14,943,000 after buying an additional 60,636 shares in the last quarter. Finally, Acadian Asset Management LLC increased its stake in shares of Supernus Pharmaceuticals by 13.8% in the third quarter. Acadian Asset Management LLC now owns 1,737,526 shares of the specialty pharmaceutical company’s stock worth $42,967,000 after buying an additional 210,249 shares in the last quarter. 93.46% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) opened at 25.10 on Friday. The firm has a 50-day moving average of $23.78 and a 200 day moving average of $22.41. The company has a market cap of $1.24 billion, a PE ratio of 51.22 and a beta of 1.88. Supernus Pharmaceuticals, Inc. has a 52-week low of $9.51 and a 52-week high of $27.50.

ILLEGAL ACTIVITY NOTICE: “Supernus Pharmaceuticals, Inc. (SUPN) Position Decreased by Strs Ohio” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be read at http://www.watchlistnews.com/supernus-pharmaceuticals-inc-supn-position-decreased-by-strs-ohio/1061368.html.

A number of brokerages recently weighed in on SUPN. Cantor Fitzgerald reaffirmed a “buy” rating and set a $32.00 price objective on shares of Supernus Pharmaceuticals in a research report on Thursday. Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 30th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, November 16th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $26.20.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

5 Day Chart for NASDAQ:SUPN

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.